← Back to Search

Ketone Supplement

Ketone Supplementation for Eating Disorders

N/A

Recruiting

Led By Guido Frank, MD

Research Sponsored by University of California, San Diego

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Must currently meet DSM-5 criteria for Anorexia Nervosa, Bulimia Nervosa, or OSFED Anorexia or Bulimia Nervosa based on the MINI diagnostic interview

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up change from baseline to study completion, up to 2 weeks

Awards & highlights

Study Summary

This trial will study the effects of ketone supplements on eating habits, mood, and anxiety in people with anorexia or bulimia.

Who is the study for?

This trial is for individuals with Anorexia Nervosa, Bulimia Nervosa, or OSFED related to these conditions. Participants must be medically stable and able to communicate in English. They should respond promptly to study messages up to six times a day. People with certain medical conditions, recent substance abuse, significant brain trauma, intellectual disabilities or allergies to the drink's ingredients cannot join.Check my eligibility

What is being tested?

The study examines how a Kenetik Ketone Drink affects eating behaviors, mood and anxiety in those with anorexia or bulimia nervosa. It includes initial EEG tests after taking either the ketone drink or placebo on two consecutive days (randomized), followed by two weeks of twice-daily ketone supplementation.See study design

What are the potential side effects?

Potential side effects are not detailed but may include reactions typical of dietary supplements such as digestive discomfort. Specific risks could relate to ingredients like D-BHB and various additives present in the KenetikR drink.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

I have been diagnosed with an eating disorder (Anorexia, Bulimia, or OSFED).

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ change from baseline to study completion, up to 2 weeks

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~change from baseline to study completion, up to 2 weeks

This trial's timeline: 3 weeks for screening, Varies for treatment, and change from baseline to study completion, up to 2 weeks for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Eating Disorders

Weight Change

Trial Design

1Treatment groups

Experimental Treatment

Group I: Ketone SupplementationExperimental Treatment1 Intervention

Subjects will ingest 2 daily doses of Kenetik ketone drink supplementation for 14 days.

0 / 1Eligibility criteria met

Find a Location

Who is running the clinical trial?

University of California, San DiegoLead Sponsor

1,120 Previous Clinical Trials

1,521,367 Total Patients Enrolled

15 Trials studying Anorexia Nervosa

1,574 Patients Enrolled for Anorexia Nervosa

Guido Frank, MDPrincipal InvestigatorUniversity of California, San Diego

5 Previous Clinical Trials

435 Total Patients Enrolled

5 Trials studying Anorexia Nervosa

435 Patients Enrolled for Anorexia Nervosa

Media Library

Kenetik Ketone Drink (Ketone Supplement) Clinical Trial Eligibility Overview. Trial Name: NCT05507008 — N/A

Anorexia Nervosa Research Study Groups: Ketone Supplementation

Anorexia Nervosa Clinical Trial 2023: Kenetik Ketone Drink Highlights & Side Effects. Trial Name: NCT05507008 — N/A

Kenetik Ketone Drink (Ketone Supplement) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05507008 — N/A

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Does this research encompass those aged 75 and above?

"This trial mandates that participants are no younger than 18 years old and not beyond 65."

Answered by AI

Is recruitment for this experiment still taking place?

"According to clinicaltrials.gov, this trial is still looking for participants and has been accepting applications since October 13th 2022. It was last updated on the 31st of October in the same year."

Answered by AI

How many people are actively participating in this medical experiment?

"Affirmative. According to clinicaltrials.gov, the trial is still recruiting participants; having been initially posted on October 13th 2022 and modified as recently as October 31st of that same year. 40 individuals are necessary for this singular site-based experiment."

Answered by AI

What are the eligibility criteria for participating in this trial?

"Forty applicants aged between 18 and 65 who have been clinically diagnosed with anorexia nervosa, bulimia nervosa or OSFED-related eating disorders can participate in this research. Additionally, they must be medically stable following a full medical assessment by the study physician; speak English as their native language; and demonstrate ability to respond to electronic messages up to 6 times daily within one hour of receiving them."

Answered by AI

Recent research and studies

Molecular PsychiatryJournal

The Effects of Ketamine on Dopaminergic Function: Meta-analysis and Review of the Implications for Neuropsychiatric Disorders

Kokkinou, M, A H Ashok, and O D Howes. 2017. “The Effects of Ketamine on Dopaminergic Function: Meta-analysis and Review of the Implications for Neuropsychiatric Disorders”. Molecular Psychiatry. Springer Science and Business Media LLC. doi:10.1038/mp.2017.190.

Neuroscience & Biobehavioral ReviewsJournal

Ketogenic Diet as a Metabolic Therapy for Mood Disorders: Evidence and Developments

Brietzke, Elisa, Rodrigo B. Mansur, Mehala Subramaniapillai, Vicent Balanzá-Martínez, Maj Vinberg, Ana González-Pinto, Joshua D. Rosenblat, Roger Ho, and Roger S. McIntyre. 2018. “Ketogenic Diet as a Metabolic Therapy for Mood Disorders: Evidence and Developments”. Neuroscience & Biobehavioral Reviews. Elsevier BV. doi:10.1016/j.neubiorev.2018.07.020.

Brain ResearchJournal

Ketogenic Diet Protects Dopaminergic Neurons Against 6-OHDA Neurotoxicity via Up-regulating Glutathione in a Rat Model of Parkinson's Disease

Cheng, Baohua, Xinxin Yang, Liangxiang An, Bo Gao, Xia Liu, and Shuwei Liu. 2009. “Ketogenic Diet Protects Dopaminergic Neurons Against 6-OHDA Neurotoxicity via Up-regulating Glutathione in a Rat Model of Parkinson's Disease”. Brain Research. Elsevier BV. doi:10.1016/j.brainres.2009.06.060.

QjmJournal